Revefenacin

Revefenacin
Clinical data
Trade names	Yupelri
AHFS/Drugs.com	Monograph
MedlinePlus	a619009
License data	US DailyMed: Revefenacin ;
Routes of; administration	Inhalation
ATC code	R03BB08 ( WHO );
Legal status
Legal status	US: ℞-only ;
Identifiers
CAS Number	864750-70-9 ;
PubChem CID	11753673 ;
DrugBank	DB11855 ;
ChemSpider	9928376 ;
UNII	G2AE2VE07O ;
KEGG	D10978 ;
CompTox Dashboard (EPA)	DTXSID701027775 ;
Chemical and physical data
Formula	C35H43N5O4
Molar mass	597.760 g·mol−1
3D model (JSmol)	Interactive image ;
	SMILES CN(CCN1CCC(CC1)OC(=O)NC2=CC=CC=C2C3=CC=CC=C3)C(=O)C4=CC=C(C=C4)CN5CCC(CC5)C(=O)N;
	InChI InChI=1S/C35H43N5O4/c1-38(34(42)29-13-11-26(12-14-29)25-40-19-15-28(16-20-40)33(36)41)23-24-39-21-17-30(18-22-39)44-35(43)37-32-10-6-5-9-31(32)27-7-3-2-4-8-27/h2-14,28,30H,15-25H2,1H3,(H2,36,41)(H,37,43); Key:FYDWDCIFZSGNBU-UHFFFAOYSA-N;

Last updated September 13, 2025

Revefenacin, sold under the brand name Yupelri, is a medication for the treatment of chronic obstructive pulmonary disease (COPD). It was approved for use in the United States in 2018.^[1] It was developed by Theravance Biopharma and is marketed by Mylan. Revefenacin is formulated as a solution that is nebulized and inhaled.^[2]

Society and culture

Brand names

In some countries, Yupelri is marketed by Viatris after Upjohn merged with Mylan to create Viatris.^[4]^[5]

References

↑ "Theravance Biopharma and Mylan Receive FDA Approval for Yupelri (revefenacin) in Adults with Chronic Obstructive Pulmonary Disease" (Press release). Mylan. 9 November 2018. Archived from the original on 15 September 2019. Retrieved 17 January 2019.
↑ Heo YA (January 2019). "Revefenacin: First Global Approval". Drugs. 79 (1): 85–91. doi:10.1007/s40265-018-1036-x. PMC 6445810 . PMID 30560478.
↑ Donohue JF, Kerwin E, Barnes CN, Moran EJ, Haumann B, Crater GD (May 2020). "Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis". BMC Pulmonary Medicine. 20 (1) 134. doi: 10.1186/s12890-020-1156-4 . PMC 7216337 . PMID 32393215.
↑ "Pfizer Completes Transaction to Combine Its Upjohn Business with Mylan". Pfizer. 16 November 2020. Retrieved 17 June 2024– via Business Wire.
↑ "Brands". Viatris. 16 November 2020. Retrieved 17 June 2024.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] "Theravance Biopharma and Mylan Receive FDA Approval for Yupelri (revefenacin) in Adults with Chronic Obstructive Pulmonary Disease" (Press release). Mylan. 9 November 2018. Archived from the original on 15 September 2019. Retrieved 17 January 2019.

[2] Heo YA (January 2019). "Revefenacin: First Global Approval". Drugs. 79 (1): 85–91. doi:10.1007/s40265-018-1036-x. PMC 6445810 . PMID 30560478.

[pmid32393215-3] Donohue JF, Kerwin E, Barnes CN, Moran EJ, Haumann B, Crater GD (May 2020). "Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis". BMC Pulmonary Medicine. 20 (1) 134. doi: 10.1186/s12890-020-1156-4 . PMC 7216337 . PMID 32393215.

[4] "Pfizer Completes Transaction to Combine Its Upjohn Business with Mylan". Pfizer. 16 November 2020. Retrieved 17 June 2024– via Business Wire.

[5] "Brands". Viatris. 16 November 2020. Retrieved 17 June 2024.

[1]

[2]

[3]

[4]

[5]

Revefenacin

Contents

Society and culture

Brand names

References